At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced … Continue reading “UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System”
Author: Ian Schofield
Ian Schofield has been writing on issues affecting the pharmaceutical and biotech industry since the mid-1980s. He writes for Scrip and Pink Sheet and can be contacted at [email protected].